DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.

DBV Technologies is a global clinical stage biopharmaceutical company that develops epicutaneous immunotherapy for food allergies and other immunological diseases. Self-described.

DBV Technologies

DBV Technologies | 16,493 followers on LinkedIn. On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™ | DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.

We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.

This mission drives our commitment to the advancement of treatments for patients and their families.

Vincent DIOSZEGHY

LifeSci Advisors-LS Associates

Will de Groot

Freelance Photographer at Thomas Raffoux Photography

Thomas Raffoux

Chief Medical Officer at Sitryx Therapeutics

Ravi Rao

DBV is proud to sponsor FAACT, Food Allergy & Anaphylaxis Connection Team 's Digital Influencer Summit and tenth annual Global Food Industry and Research Summit. We look forward to connecting with peers to explore how to safely meet the needs of the #FoodAllergy community. Stop by our booth to learn more: https://bit.ly/40CQskp

Today, we reported financial results for the third quarter of 2024. Read the full press release here: https://bit.ly/4hEPzhe

We look forward to joining our #FoodAllergy peers at the upcoming American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, where we will be hosting a product theater on Saturday, October 26. Visit us at our booth to learn more about our potential treatment for those with peanut allergy. Details here: https://bit.ly/3NGNPWZ

We are pleased to announce positive regulatory updates for our investigational product, the Viaskin® Peanut Patch, including guidance on a pathway for Accelerated Approval for toddlers ages 1-3 with #PeanutAllergy . Join our conference call at 5pm ET for more: https://bit.ly/4hfTfpC

Our CMO, Pharis Mohideen , participated in a panel at FARE Neighborhoods Day about using data & research to navigate the landscapes of our neighborhoods to create more equitable futures for those with #FoodAllergies . We're grateful for the opportunity to participate in inspiring dialogue to move toward a more inclusive and healthy future for all.

Our team had the pleasure of connecting with members of the #allergy community for Allergy & Asthma Network 's annual #CorporateCouncil meeting. It was great to come together and discuss ways to empower patients and create a healthier future for all.

🔬 Our innovative technology platform merges science and technology to change the way we think about #allergy treatment. It allows us to explore the potential of the Viaskin® patch and epicutaneous immunotherapy for children with #PeanutAllergy . Learn more here: https://bit.ly/4b5svUE

In case you missed it, KSTP Minnesota explores the development of our investigational pediatric #PeanutAllergy treatment with Dr. Doug McMahon of the Asthma & Allergy Center of Minnesota and our CMO, Dr. Pharis Mohideen, featuring insights from a mother of a peanut-allergic child. Watch here to learn more: https://bit.ly/4guSbhe

Don't miss our lunch symposium at this year's World Allergy Congress. We will discuss our work to advance our lead candidate for the treatment of #PeanutAllergy . Learn more about the congress here: https://bit.ly/3MO4ub1 World Allergy Organization

We are proud to share that we've completed screening for our VITESSE Phase 3 #ClinicalTrial for children ages 4-7 with a #PeanutAllergy . We look forward to further advancing our clinical development program. Read more in our press release: https://bit.ly/4gxNxiD

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue									5.71M -	4.80M 15.91%
cost of revenue							2.72M -	15.34M 463.27%			-4.16M -
gross profit							-2.72M -	-15.34M 463.27%	5.71M 137.20%	4.80M 15.91%	4.16M 13.34%
selling and marketing expenses							21.22M -	9.88M 53.44%	4.39M 55.59%	1.60M 63.53%	-1.81M 213.06%
general and administrative expenses							49.16M -	34.14M 30.55%	30.52M 10.60%	24.30M 20.38%	22.88M 5.86%
selling general and administrative expenses							70.37M -	44.02M 37.45%	34.91M 20.70%	25.90M 25.80%	21.07M 18.66%
research and development expenses							113.69M -	101.61M 10.63%	70.34M 30.78%	75.50M 7.34%	68.34M 9.49%
other expenses	-5.03M -	-5.53M 9.96%	-6.44M 16.37%	-9.36M 45.42%	-13.78M 47.16%	-14.66M 6.39%	-14.14M 3.56%	-10.33M 26.92%
cost and expenses							169.93M -	135.29M 20.38%	105.24M 22.21%	101.40M 3.65%	85.25M 15.93%
operating expenses	27.66M -	30.05M 8.63%	49.88M 65.99%	122.03M 144.66%	173.94M 42.54%	190.12M 9.30%	169.93M 10.62%	135.29M 20.38%	105.24M 22.21%	101.40M 3.65%	89.41M 11.83%
interest expense							1.58M -	724K 54.13%		427K -
ebitda								-124.83M -	-100.45M 19.53%	-96.60M 3.84%	-89.41M 7.45%
operating income								-158.84M -	-98.61M 37.92%	-96.63M 2.01%	-85.25M 11.78%
depreciation and amortization							6.46M -	34.01M 426.38%	-1.84M 105.41%	31K 101.68%	-4.16M 13,518.04%
total other income expenses net								-727K -	424K 158.32%	431K 1.65%	9.87M 2,191.18%
income before tax								-159.57M -	-98.19M 38.47%	-96.20M 2.03%	-75.37M 21.65%
income tax expense							610.49K -	-10K 101.64%	-381K 3,710%	100K 126.25%	-8.10M 8,201.82%
net income	-26.66M -	-29.20M 9.52%	-48.84M 67.27%	-120.45M 146.62%	-177.19M 47.10%	-189.97M 7.22%	-172.04M 9.44%	-159.56M 7.26%	-97.81M 38.70%	-96.30M 1.54%	-67.27M 30.15%
weighted average shs out	13.60M -	16.09M 18.24%	21.52M 33.79%	24.45M 13.63%	24.76M 1.24%	28.92M 16.83%	37.01M 27.94%	54.09M 46.17%	54.92M 1.52%	77.66M 41.42%	95.12M 22.48%
weighted average shs out dil	13.60M -	16.09M 18.24%	21.52M 33.79%	24.45M 13.63%	24.76M 1.24%	28.92M 16.83%	37.01M 27.94%	54.09M 46.17%	54.92M 1.52%	77.66M 41.42%	95.12M 22.48%
eps	-1.96 -	-1.82 7.14%	-2.27 24.73%	-4.93 117.18%	-7.16 45.23%	-6.57 8.24%	-4.65 29.22%	-2.95 36.56%	-1.78 39.66%	-1.24 30.34%	-0.71 42.74%
epsdiluted	-1.96 -	-1.82 7.14%	-2.27 24.73%	-4.93 117.18%	-7.16 45.23%	-6.57 8.24%	-4.65 29.22%	-2.95 36.56%	-1.78 39.66%	-1.24 30.34%	-0.71 42.74%

COM:DBV-TECHNOLOGIES

DBV Technologies

Last Close

0.51

22/11 16:35

Market Cap

73.81M

Beta: -

Volume Today

382.51K

Avg: -

Preview